Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2016
NICE & PBAC outcomes differ for new heart failure drug Entresto
27 April 2016 - Around 100,000 people in England and Wales could now benefit from treatment with Novartis’ revolutionary heart failure ...
Posted by Michael Wonder on 27 Apr 2016
NICE recommends ovarian cancer treatments
27 April 2016 - NICE has published final guidance for five ovarian cancer drugs. Three of the drugs are not recommended, ...
Posted by Michael Wonder on 22 Apr 2016
NICE recommends Jevtana (cabazitaxel) for prostate cancer
22 April 2016 - NICE has issued final guidance recommending cabazitaxel (Jevtana, Sanofi) for some prostate cancer patients. This is a ...
Posted by Michael Wonder on 15 Apr 2016
NICE recommends ataluren for treating Duchenne muscular dystrophy caused by a nonsense mutation
15 April 2016 - NICE has today recommended ataluren (Translarna, PTC Therapeutics) for treating children aged 5 and over with Duchenne ...
Posted by Michael Wonder on 08 Apr 2016
NICE appraisal consultation for azacitidine (Vidaza) for patients with acute myeloid leukaemia
8 April 2016 - The Department of Health has asked NICE to produce guidance on the use of azacitidine in the ...
Posted by Michael Wonder on 27 Mar 2016
Welsh Government overrules NICE's rejection of Celgene's pancreatic cancer drug Abraxane
18 March 2016 - Patients with pancreatic cancer living in Wales will no doubt welcome news that Celgene’s Abraxane will continue ...
Posted by Michael Wonder on 23 Mar 2016
NICE consults on draft guidance for new cystic fibrosis treatment
23 March 2016 - NICE has issued draft guidance which does not recommend Orkambi (lumacaftor-ivacaftor marketed by Vertex Pharmaceuticals) for treating ...
Posted by Michael Wonder on 21 Mar 2016
NICE recommends abiraterone acetate for prostate cancer
21 March 2016 - NICE has issued final guidance recommending abiraterone (marketed as Zytiga by Janssen) for some prostate cancer patients*. ...
Posted by Michael Wonder on 21 Mar 2016
NICE confirms support for Novartis' heart drug Entresto
20 March 2016 - Cost regulators for the National Health Service in England and Wales have reiterated their support for the ...
Posted by Michael Wonder on 16 Mar 2016
NICE consults on ‘no’ recommendation for skin cancer drug talimogene laherparepvec
16 March 2016 - NICE has today issued draft guidance not recommending talimogene laherparepvec (Imlygic, Amgen) as an option for people ...
Posted by Michael Wonder on 08 Mar 2016
NICE to reject Humira for inflammatory skin disease
8 March 2016 - Cost regulators for the NHS in England and Wales are leaning towards a ‘no’ on the use ...
Posted by Michael Wonder on 02 Mar 2016
UK cost agency rejects leukaemia drug from J&J and AbbVie
1 March 2016 - A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's ...
Posted by Michael Wonder on 25 Feb 2016
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 - Praxbind (idarucizumab) is now available to be used commercially in England, Ireland and Wales after the Health ...
Posted by Michael Wonder on 08 Feb 2016
NICE issues draft guidance on alirocumab for lipid disorder
8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high ...
Posted by Michael Wonder on 27 Jan 2016
NICE publishes final drug recommendations for 5 separate medical conditions
27 January 2016 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...